Ten63 Therapeutics
During her over 38 years of leadership experience in big pharma, Nancy executed ~300 deals producing over $10B in value creation. Before joining Ten63 Nancy was part of the Executive Committee of Merck GHH, where she led Global BD for all areas (including KEYTRUDA), strategy, global commercial assessment and valuations and Merck GHH's digital transformation.
This person is not in the org chart
This person is not in any offices
Ten63 Therapeutics
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world’s most lethal diseases.